- Home
- » Tags
- » Deutetrabenazine
Top View
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Austedo™ (Deutetrabenazine)
- Pharmacogenetics Testing AHS – M2021
- Clévio Nóbrega Luís Pereira De Almeida Editors Polyglutamine Disorders Advances in Experimental Medicine and Biology
- Medicaid List of Covered Drugs (Formulary)
- DUR Capsules, Quarter
- Clinical Policy: Deutetrabenazine (Austedo) Reference Number: ERX.SPA.150 Effective Date: 09.01.17 Last Review Date: 05.18 Revision Log
- Tardive Syndromes
- 209885Orig1s000
- View Board (#17–0011)
- Effect of Deutetrabenazine on Chorea Among Patients with Huntington Disease a Randomized Clinical Trial
- Pharmacy Policy Statement
- AUSTEDO (Deutetrabenazine) RATIONALE for INCLUSION IN
- Protecting Deuterated Drugs
- Revisiting Amantadine As a Treatment for Drug-Induced Movement Disorders
- Deutetrabenazine
- Austedo) Reference Number: CP.PHAR.341 Effective Date: 06.13.17 Last Review Date: 08.20 Line of Business: Commercial, HIM, Medicaid Revision Log
- Specialty Products List
- Vemlidy) Tenofovir Disoproxil Fumarate (Viread
- Austedo (Deutetrabenazine) C12650-A
- 208082Orig1s000
- Update on Psychiatric Medications
- Study Protocol
- Program News
- A Novel Treatment for Chorea Associated with Huntington's Disease
- Continuing Education for Pharmacists Volume XXXVI, No
- 09-2017 Durbd Minutes Final.Pdf
- Prior Authorization — Premium
- Austedo® (Deutetrabenazine) P&T Approval Date 11/2017, 11/2018, 11/2019, 11/2020 Effective Date 2/1/2021; Oxford Only: 2/1/2021
- Appendix F: Excluded Studies
- 5.01.605 Medical Necessity Criteria for Pharmacy Edits
- Paragraph IV Patent Certifications (PPIV)
- PRESCRIBING INFORMATION Administer with Food (2.1) These Highlights Do Not Include All the Information Needed to Use AUSTEDO Safely and • Effectively
- Medications for Huntington's Disease
- AUSTEDO (Deutetrabenazine) Is a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for Oral Administration
- 209885Orig1s000
- Medicines Regulation
- FDA Approved VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia
- AUSTEDO (Deutetrabenazine) Tablets, for Oral Use Metabolizers Is 36 Mg Per Day (I.E., 18 Mg Twice Daily) (2.4, 8.7) Initial U.S
- VMAT-2 Inhibitors: Deutetrabenazine, Tetrabenazine And
- Xenazine Prescribing Information
- Study Protocol
- Deutetrabenazine for Tardive Dyskinesia
- UCSF Movement Disorders Disclosures New Direction #1
- Tardive Dyskinesia: Treatment Update
- Austedo Deutetrabenazine Molina Clinical Policy
- Behavioral Health & Recover Services San Mateo County Prior
- Drugs Limited to Specific Pharmacies | Kaiser Permanente Washington
- Effect of Deutetrabenazine on Chorea Among Patients
- Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: a Narrative Review
- Northwestern Medicine Specialty Pharmacy (NMSP) Medication List
- Drug-Induced Movement Disorders